MYC and Miyoshi myopathy: In addition to MM cell lines, JQ1 has proven to potently inhibit MYC in Merkel cell carcinoma cells (MCC-3 and 5), primary effusion lymphoma cells (PELs) and B cell acute lymphoblastic lymphomas (B-ALL) cells at the transcript level, as well as in diffuse large B cell lymphoma (DLBCL) cells at the protein expression level (Ott et al., 2012; Shao et al., 2014; Tolani et al., 2014; Trabucco et al., 2015).